Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.
about
A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsStudy of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.Conditionally replicating adenoviruses for cancer treatment.Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.Adenoviral-mediated gene transfer into the canine brain in vivo.Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer modelSafety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialHigh-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors.Turning the gene tap off; implications of regulating gene expression for cancer therapeutics.Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma ModelRegulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators.Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivo.Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain.Coxsackievirus B3 Directly Induced Th17 Cell Differentiation by Inhibiting Nup98 Expression in Patients with Acute Viral Myocarditis.Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for gliomaViral vectors for gene delivery to the central nervous system.CRISPR genome engineering and viral gene delivery: a case of mutual attraction.Sstr2A: a relevant target for the delivery of genes into human glioblastoma cells using fiber-modified adenoviral vectors.Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells.Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas.Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.Gene transfer into neural cells in vitro using adenoviral vectors.
P2860
Q33877450-4D83A68C-E392-4B9D-A54B-A50B63ECCC00Q34012284-EC8DA05A-2494-4EFB-9906-5807B30ABF91Q35870480-D68519DA-B8F5-4EC8-AC18-EDEB766468B1Q35967313-E14B4775-5A78-47B6-A18A-6E831D8EB751Q35999648-1B9745EF-3B8A-42CE-A311-D11965937858Q36172992-17EB2501-92C3-4F03-876A-979A2FE9B82AQ36345439-36B362F2-01CD-43F4-92EF-F5EDF6ACCC89Q36534329-A5762238-6B36-42FE-B5B8-387908A80065Q36540199-F3784F70-5BE5-472F-A288-3C4B5162B27EQ36658322-FB502B16-4C3D-458F-8633-FF32E53E020EQ36960666-FABDA016-9DFB-4C96-B466-FFE31BED88BAQ36983576-7A1C7F3E-EED6-4663-BEC7-2FDBFAE514B6Q36994041-090F5E53-D6B5-4853-8D6A-BC8757817AC7Q37010979-D2820247-198E-46CC-99F1-B26B811A6E87Q37050094-5639604A-5EAC-43A6-81D8-E8E0B9D8E1CBQ37079181-71124DEC-F89E-4F33-853B-3102E1D2E1D7Q37099841-6E16E0DF-5E70-45D7-8080-C486B0DA01D2Q37245006-C85DD9AA-CDF0-4310-8CEE-1E61EF199800Q37486647-5CFD3FE8-4629-47F2-B550-8FAF6AD3A0C3Q37730116-1C1EFA8B-F208-4A84-913C-9B10F8C53B1CQ37946113-26B6A966-47AA-49E7-A6F1-0F643BF042B5Q38348602-E284B327-1EFD-43E5-BF7C-D0F19C5B32FCQ39347239-D4ECCB21-EC64-4FD3-9C96-EE1935E92D8EQ39682767-DF81A862-F783-4176-9862-41B815F1B376Q40086745-D208F292-AC43-4158-B2D4-1771946250D5Q41699782-10471248-FE63-43E9-AF46-735D42EA45FBQ43157946-6542F189-2FA5-4522-A6E5-4048CD629F9B
P2860
Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effective high-capacity gutles ...... ression in human glioma cells.
@ast
Effective high-capacity gutles ...... ression in human glioma cells.
@en
type
label
Effective high-capacity gutles ...... ression in human glioma cells.
@ast
Effective high-capacity gutles ...... ression in human glioma cells.
@en
prefLabel
Effective high-capacity gutles ...... ression in human glioma cells.
@ast
Effective high-capacity gutles ...... ression in human glioma cells.
@en
P2093
P2860
P1433
P1476
Effective high-capacity gutles ...... pression in human glioma cells
@en
P2093
Altan Rentsendorj
Chunyan Liu
Donna Palmer
Hasmik Agadjanian
Kurt M Kroeger
Lali Medina-Kauwe
Marianela Candolfi
Pedro R Lowenstein
Wei-Dong Xiong
P2860
P304
P356
10.1016/J.YMTHE.2006.05.006
P577
2006-06-23T00:00:00Z